Heimdall Insights

Global Myocardial Infarction and Cardiomyopathy Therapeutics Market

Sizing, Segmentation, & Growth Forecast (2025-2030)

Last updated: August 2026

Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.

Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).

1. Summary

The Global Myocardial Infarction and Cardiomyopathy Therapeutics Market was valued at $23.8 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 4.6% CAGR, to an estimated market size of $29.8 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global Myocardial Infarction and Cardiomyopathy Therapeutics market encompasses the pharmaceutical agents, interventional technologies, and treatment protocols used to manage acute coronary syndromes and chronic heart muscle diseases. The scope includes pharmacological therapies such as antiplatelets, anticoagulants, beta-blockers, and lipid-lowering agents, as well as interventional cardiology tools like drug-eluting stents and bioresorbable scaffolds, while excluding general surgical equipment not specific to cardiac reperfusion.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Myocardial Infarction and Cardiomyopathy Therapeutics Market in the period 2025-30:

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:

Geographies

  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Segments

  • Antiplatelet Agents
  • Lipid-lowering Therapies
  • Beta-Blockers
  • ACE Inhibitors & ARBs
  • Other Therapeutics